WO2024023740 - COMBINATIONS OF RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12 WITH PD-1/PD-L1 INHIBITORS
National phase entry:
Publication Number
WO/2024/023740
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057598
International Filing Date
26.07.2023
Title **
[English]
COMBINATIONS OF RECOMBINANT VIRUS EXPRESSING INTERLEUKIN-12 WITH PD-1/PD-L1 INHIBITORS
[French]
COMBINAISONS DE VIRUS RECOMBINANT EXPRIMANT L'INTERLEUKINE-12 AVEC DES INHIBITEURS DE PD-1/PDL1
Applicants **
ASTRAZENECA AB
Inventors
OBERST, Michael David
BURKE, Shannon
KUROKAWA, Cheyne
Priority Data
63/369,605
27.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3285 | |
| EPO | Filing, Examination, Granting | 15335 | |
| Japan | Filing, Examination, Granting | 2393 | |
| South Korea | Filing, Examination, Granting | 2435 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
29,088
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to a therapeutic combination comprising (i) a recombinant poxvirus comprising in its genome a heterologous nucleic acid sequence encoding interleukin-12 (IL-12) and (ii) a PD-1 inhibitor or PD-L1 inhibitor. Methods of treating cancer and methods of enhancing a tumor-specific immune response comprising administering the therapeutic combination are also provided.[French]
La présente invention concerne une combinaison thérapeutique comprenant (i) un poxvirus recombinant comprenant dans son génome une séquence d'acide nucléique hétérologue codant pour l'interleukine-12 (IL-12) et (ii) un inhibiteur de PD-1 ou un inhibiteur de PD-L1. L'invention concerne également des méthodes de traitement du cancer et des méthodes d'amélioration d'une réponse immunitaire spécifique d'une tumeur, comprenant l'administration de la combinaison thérapeutique.